KALV stock forecast
Our latest prediction for KalVista Pharmaceuticals, Inc.'s stock price was made on the Dec. 16, 2019 when the stock price was at 16.72$.
In the short term (2weeks), KALV's stock price should underperform the market by -6.62%. During that period the price should oscillate between -11.66% and +10.37%.
In the medium term (3months), KALV's stock price should underperform the market by -15.21%. During that period the price should oscillate between -36.33% and +22.86%.Get email alerts
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
At the moment the company generates 14M USD in revenues.
On its last earning announcement, the company reported a loss of -1.49$ per share.
The book value per share is 1.53$
Three months stock forecastDec. 16, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|